Author

Gregory Hubbard

Masonic Cancer CenterORCID 0009-0003-2417-1576Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Elizabeth C MorganiD· 1 shared Enoc Granados CentenoiD· 1 shared Hrishi VenkateshiD· 1 shared Lynn M. Heltemes-HarrisiD· 1 shared Michael A. FarrariD· 1 shared Sean I. TracyiD· 1 shared Taylor L Maiers· 1 shared Thamotharampillai DileepaniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

8 top collaborators · 28 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Elizabeth C MorganORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ImmunologybioRxivPreprintJul 2, 2025

PDL1 CHECKPOINT BLOCKADE SYNERGIZES WITH NILOTINIB BUT NOT DASATINIB TO PREVENT LEUKEMIA RELAPSE

Elizabeth C Morgan, Hrishi Venkatesh, Enoc Granados Centeno…·Michael A. Farrar

This study compares the effects of nilotinib and dasatinib on anti-leukemia immune responses when combined with PD-L1 blockade, finding that nilotinib synergizes with PD-L1 blockade to prevent relapse while dasatinib does not.

DOI 10.1101/2025.07.02.662848

mouseexperimental assay

𝕏 PostBluesky